Erratum

Kowtoniuk RA, Liu YE, Jeter JP. Cutaneous cold weather injuries in the US Military. Cutis. 2021;108:181-184, 202. doi:10.12788/cutis.0363

In the article above from the October 2021 issue, an author’s name was spelled incorrectly. The correct byline appears below. The article has been corrected online at www.mdedge.com/dermatology. We apologize for the error.

Robert A. Kowtoniuk, DO; Yizhen E. Liu, MD; Jonathan P. Jeter, MD

Kowtoniuk RA, Liu YE, Jeter JP. Cutaneous cold weather injuries in the US Military. Cutis. 2021;108:181-184, 202. doi:10.12788/cutis.0363

In the article above from the October 2021 issue, an author’s name was spelled incorrectly. The correct byline appears below. The article has been corrected online at www.mdedge.com/dermatology. We apologize for the error.

Robert A. Kowtoniuk, DO; Yizhen E. Liu, MD; Jonathan P. Jeter, MD

Kowtoniuk RA, Liu YE, Jeter JP. Cutaneous cold weather injuries in the US Military. Cutis. 2021;108:181-184, 202. doi:10.12788/cutis.0363

In the article above from the October 2021 issue, an author’s name was spelled incorrectly. The correct byline appears below. The article has been corrected online at www.mdedge.com/dermatology. We apologize for the error.

Robert A. Kowtoniuk, DO; Yizhen E. Liu, MD; Jonathan P. Jeter, MD

The author would like to make the following correction to the Editorial, originally published in the July issue of the Journal of Hospital Medicine 2020;15(7):447-448. DOI 10.12788/jhm.3468. In the third paragraph, MINS was described as an “umbrella term that can indicate either a myocardial infarction (MI) or nonischemic myocardial injury (NIMI).” This is not fully accurate: MINS is an umbrella term that can indicate either an MI or other myocardial injury due to ischemia. The correction to the paragraph is as follows, indicated in bold type:

In this journal issue, Cohn and colleagues summarize the current information around this phenomenon of myocardial injury after noncardiac surgery, or MINS.¹ Consistent with the literature, they define MINS as an acute rise and/or fall in troponin (above the assay’s upper limit of normal) at any point in the 30 days following noncardiac surgery. Importantly, MINS is an umbrella term that can indicate either an MI or other myocardial injury due to ischemia. An MI exists if there are clinical signs of ischemia and/or objective evidence of infarction on imaging.

The author would like to make the following correction to the Editorial, originally published in the July issue of the Journal of Hospital Medicine 2020;15(7):447-448. DOI 10.12788/jhm.3468. In the third paragraph, MINS was described as an “umbrella term that can indicate either a myocardial infarction (MI) or nonischemic myocardial injury (NIMI).” This is not fully accurate: MINS is an umbrella term that can indicate either an MI or other myocardial injury due to ischemia. The correction to the paragraph is as follows, indicated in bold type:

In this journal issue, Cohn and colleagues summarize the current information around this phenomenon of myocardial injury after noncardiac surgery, or MINS.¹ Consistent with the literature, they define MINS as an acute rise and/or fall in troponin (above the assay’s upper limit of normal) at any point in the 30 days following noncardiac surgery. Importantly, MINS is an umbrella term that can indicate either an MI or other myocardial injury due to ischemia. An MI exists if there are clinical signs of ischemia and/or objective evidence of infarction on imaging.

The author would like to make the following correction to the Editorial, originally published in the July issue of the Journal of Hospital Medicine 2020;15(7):447-448. DOI 10.12788/jhm.3468. In the third paragraph, MINS was described as an “umbrella term that can indicate either a myocardial infarction (MI) or nonischemic myocardial injury (NIMI).” This is not fully accurate: MINS is an umbrella term that can indicate either an MI or other myocardial injury due to ischemia. The correction to the paragraph is as follows, indicated in bold type:

In this journal issue, Cohn and colleagues summarize the current information around this phenomenon of myocardial injury after noncardiac surgery, or MINS.¹ Consistent with the literature, they define MINS as an acute rise and/or fall in troponin (above the assay’s upper limit of normal) at any point in the 30 days following noncardiac surgery. Importantly, MINS is an umbrella term that can indicate either an MI or other myocardial injury due to ischemia. An MI exists if there are clinical signs of ischemia and/or objective evidence of infarction on imaging.

A correction has been made to the Figure. A dosage was incorrect in the Orderset 1.1 (1/1/16-3/19/17) box. The figure listed Insulin 19 Units IV x 1 and should have been Insulin 10 Units IV x 1. Below is the corrected figure..

A correction has been made to the Figure. A dosage was incorrect in the Orderset 1.1 (1/1/16-3/19/17) box. The figure listed Insulin 19 Units IV x 1 and should have been Insulin 10 Units IV x 1. Below is the corrected figure..

A correction has been made to the Figure. A dosage was incorrect in the Orderset 1.1 (1/1/16-3/19/17) box. The figure listed Insulin 19 Units IV x 1 and should have been Insulin 10 Units IV x 1. Below is the corrected figure..

The article "Handheld Reflectance Confocal Microscopy to Aid in the Management of Complex Facial Lentigo Maligna" (Cutis. 2017;99:346-352) contained an error in the author affiliations. The affiliations should have read:

All from the Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York. Dr. Yélamos also is from the Dermatology Department, Hospital Clínic, Universitat de Barcelona, Spain. Dr. Rossi also is from the Department of Dermatology, Weill Cornell Medical College, New York.

The staff of Cutis^® makes every possible effort to ensure accuracy in its articles and apologizes for the mistake.

The article "Handheld Reflectance Confocal Microscopy to Aid in the Management of Complex Facial Lentigo Maligna" (Cutis. 2017;99:346-352) contained an error in the author affiliations. The affiliations should have read:

All from the Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York. Dr. Yélamos also is from the Dermatology Department, Hospital Clínic, Universitat de Barcelona, Spain. Dr. Rossi also is from the Department of Dermatology, Weill Cornell Medical College, New York.

The staff of Cutis^® makes every possible effort to ensure accuracy in its articles and apologizes for the mistake.

The article "Handheld Reflectance Confocal Microscopy to Aid in the Management of Complex Facial Lentigo Maligna" (Cutis. 2017;99:346-352) contained an error in the author affiliations. The affiliations should have read:

All from the Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York. Dr. Yélamos also is from the Dermatology Department, Hospital Clínic, Universitat de Barcelona, Spain. Dr. Rossi also is from the Department of Dermatology, Weill Cornell Medical College, New York.

The staff of Cutis^® makes every possible effort to ensure accuracy in its articles and apologizes for the mistake.

Due to a submission error, the article “A Boxed Warning for Inadequate Psoriasis Treatment” (Cutis. 2016;98:206-207) did not contain the complete author disclosure information. The corrected disclosure statement appears below:

Ms. Kagha and Ms. Anderson report no conflict of interest. Dr. Blauvelt has served as a clinical study investigator and scientific adviser for AbbVie Inc; Amgen, Inc; Boehringer Ingelheim; Celgene Corporation; Dermira Inc; Eli Lilly and Company; Genentech, Inc; GlaxoSmithKline; Janssen Biotech, Inc; Merck & Co; Novartis; Pfizer Inc; Regeneron Pharmaceuticals, Inc; Sandoz, a Novartis Division; Sanofi; Sun Pharmaceutical Industries, Ltd; UCB; and Valeant Pharmaceuticals International, Inc, as well as a paid speaker for Eli Lilly and Company. Dr. Leonardi has served as an advisory board member and consultant for AbbVie Inc; Amgen, Inc; Boehringer Ingelheim; Dermira Inc; Eli Lilly and Company; Janssen Biotech, Inc; LEO Pharma; Pfizer Inc; Sandoz, a Novartis Division; UCB; and Vitae Pharmaceuticals. He also has been an investigator for AbbVie Inc; Actavis Pharma, Inc; Amgen, Inc; Boehringer Ingelheim; Celgene Corporation; Coherus BioSciences; Corrona, LLC; Dermira Inc; Eli Lilly and Company; Galderma Laboratories, LP; Glenmark Pharmaceuticals Inc; Janssen Biotech, Inc; LEO Pharma; Merck & Co; Novartis; Pfizer Inc; Sandoz, a Novartis Division; Stiefel, a GSK company; and Wyeth Pharmaceuticals, Inc. Dr. Leonardi also has been on the speaker’s bureau for AbbVie Inc; Celgene Corporation; Eli Lilly and Company; and Novartis. Dr. Feldman is a consultant, researcher, and/or speaker for AbbVie Inc; Amgen, Inc; Baxter; Boehringer Ingelheim; Celgene Corporation; Janssen Biotech, Inc; Merck & Co; Mylan; Novartis; Pfizer Inc; and Valeant Pharmaceuticals International, Inc.

The staff of Cutis^® makes every possible effort to ensure accuracy in its articles and apologizes for the mistake.

Due to a submission error, the article “A Boxed Warning for Inadequate Psoriasis Treatment” (Cutis. 2016;98:206-207) did not contain the complete author disclosure information. The corrected disclosure statement appears below:

Ms. Kagha and Ms. Anderson report no conflict of interest. Dr. Blauvelt has served as a clinical study investigator and scientific adviser for AbbVie Inc; Amgen, Inc; Boehringer Ingelheim; Celgene Corporation; Dermira Inc; Eli Lilly and Company; Genentech, Inc; GlaxoSmithKline; Janssen Biotech, Inc; Merck & Co; Novartis; Pfizer Inc; Regeneron Pharmaceuticals, Inc; Sandoz, a Novartis Division; Sanofi; Sun Pharmaceutical Industries, Ltd; UCB; and Valeant Pharmaceuticals International, Inc, as well as a paid speaker for Eli Lilly and Company. Dr. Leonardi has served as an advisory board member and consultant for AbbVie Inc; Amgen, Inc; Boehringer Ingelheim; Dermira Inc; Eli Lilly and Company; Janssen Biotech, Inc; LEO Pharma; Pfizer Inc; Sandoz, a Novartis Division; UCB; and Vitae Pharmaceuticals. He also has been an investigator for AbbVie Inc; Actavis Pharma, Inc; Amgen, Inc; Boehringer Ingelheim; Celgene Corporation; Coherus BioSciences; Corrona, LLC; Dermira Inc; Eli Lilly and Company; Galderma Laboratories, LP; Glenmark Pharmaceuticals Inc; Janssen Biotech, Inc; LEO Pharma; Merck & Co; Novartis; Pfizer Inc; Sandoz, a Novartis Division; Stiefel, a GSK company; and Wyeth Pharmaceuticals, Inc. Dr. Leonardi also has been on the speaker’s bureau for AbbVie Inc; Celgene Corporation; Eli Lilly and Company; and Novartis. Dr. Feldman is a consultant, researcher, and/or speaker for AbbVie Inc; Amgen, Inc; Baxter; Boehringer Ingelheim; Celgene Corporation; Janssen Biotech, Inc; Merck & Co; Mylan; Novartis; Pfizer Inc; and Valeant Pharmaceuticals International, Inc.

The staff of Cutis^® makes every possible effort to ensure accuracy in its articles and apologizes for the mistake.

Due to a submission error, the article “A Boxed Warning for Inadequate Psoriasis Treatment” (Cutis. 2016;98:206-207) did not contain the complete author disclosure information. The corrected disclosure statement appears below:

Ms. Kagha and Ms. Anderson report no conflict of interest. Dr. Blauvelt has served as a clinical study investigator and scientific adviser for AbbVie Inc; Amgen, Inc; Boehringer Ingelheim; Celgene Corporation; Dermira Inc; Eli Lilly and Company; Genentech, Inc; GlaxoSmithKline; Janssen Biotech, Inc; Merck & Co; Novartis; Pfizer Inc; Regeneron Pharmaceuticals, Inc; Sandoz, a Novartis Division; Sanofi; Sun Pharmaceutical Industries, Ltd; UCB; and Valeant Pharmaceuticals International, Inc, as well as a paid speaker for Eli Lilly and Company. Dr. Leonardi has served as an advisory board member and consultant for AbbVie Inc; Amgen, Inc; Boehringer Ingelheim; Dermira Inc; Eli Lilly and Company; Janssen Biotech, Inc; LEO Pharma; Pfizer Inc; Sandoz, a Novartis Division; UCB; and Vitae Pharmaceuticals. He also has been an investigator for AbbVie Inc; Actavis Pharma, Inc; Amgen, Inc; Boehringer Ingelheim; Celgene Corporation; Coherus BioSciences; Corrona, LLC; Dermira Inc; Eli Lilly and Company; Galderma Laboratories, LP; Glenmark Pharmaceuticals Inc; Janssen Biotech, Inc; LEO Pharma; Merck & Co; Novartis; Pfizer Inc; Sandoz, a Novartis Division; Stiefel, a GSK company; and Wyeth Pharmaceuticals, Inc. Dr. Leonardi also has been on the speaker’s bureau for AbbVie Inc; Celgene Corporation; Eli Lilly and Company; and Novartis. Dr. Feldman is a consultant, researcher, and/or speaker for AbbVie Inc; Amgen, Inc; Baxter; Boehringer Ingelheim; Celgene Corporation; Janssen Biotech, Inc; Merck & Co; Mylan; Novartis; Pfizer Inc; and Valeant Pharmaceuticals International, Inc.

The staff of Cutis^® makes every possible effort to ensure accuracy in its articles and apologizes for the mistake.

The photo challenge “Sessile Pink Plaque on the Lower Back” (Cutis. 2015;96:E3-E5) contained an error in the byline. The author names should have read:

Robyn Marszalek, MD; Phyu P. Aung, MD, PhD; Deon Wolpowitz, MD, PhD; Amy Yuntzu-Yen Chen, MD

The staff of Cutis^® makes every possible effort to ensure accuracy in its articles and apologizes for the mistake.

The photo challenge “Sessile Pink Plaque on the Lower Back” (Cutis. 2015;96:E3-E5) contained an error in the byline. The author names should have read:

Robyn Marszalek, MD; Phyu P. Aung, MD, PhD; Deon Wolpowitz, MD, PhD; Amy Yuntzu-Yen Chen, MD

The staff of Cutis^® makes every possible effort to ensure accuracy in its articles and apologizes for the mistake.

The photo challenge “Sessile Pink Plaque on the Lower Back” (Cutis. 2015;96:E3-E5) contained an error in the byline. The author names should have read:

Robyn Marszalek, MD; Phyu P. Aung, MD, PhD; Deon Wolpowitz, MD, PhD; Amy Yuntzu-Yen Chen, MD

The staff of Cutis^® makes every possible effort to ensure accuracy in its articles and apologizes for the mistake.

The article “What Is Your Diagnosis? Tinea Corporis” (Cutis. 2015;96:297, 326) contained an error in the author affiliations. The text should have stated:

Ms. Gyurjyan is from the University of Virginia School of Medicine, Charlottesville. Dr. Wilson is from the Department of Dermatology, University of Virginia Health System, Charlottesville.

The staff of Cutis^® makes every possible effort to ensure accuracy in its articles and apologizes for the mistake.

The article “What Is Your Diagnosis? Tinea Corporis” (Cutis. 2015;96:297, 326) contained an error in the author affiliations. The text should have stated:

Ms. Gyurjyan is from the University of Virginia School of Medicine, Charlottesville. Dr. Wilson is from the Department of Dermatology, University of Virginia Health System, Charlottesville.

The staff of Cutis^® makes every possible effort to ensure accuracy in its articles and apologizes for the mistake.

The article “What Is Your Diagnosis? Tinea Corporis” (Cutis. 2015;96:297, 326) contained an error in the author affiliations. The text should have stated:

Ms. Gyurjyan is from the University of Virginia School of Medicine, Charlottesville. Dr. Wilson is from the Department of Dermatology, University of Virginia Health System, Charlottesville.

The staff of Cutis^® makes every possible effort to ensure accuracy in its articles and apologizes for the mistake.

Due to a submission error, the article “Reduced Degree of Irritation During a Second Cycle of Ingenol Mebutate Gel 0.015% for the Treatment of Actinic Keratosis” (Cutis. 2015;95:47-51) contained the incorrect scale for local skin reactions (LSRs). The text in the Methods should have stated:

Using standardized photographic guides, 6 individual LSRs—erythema, flaking/scaling, crusting, 
swelling, vesiculation/pustulation, and erosion/ulceration—were assessed on a scale of 0 (none) to 
4 (severe), with higher numbers indicating more severe reactions.

The staff of Cutis^® makes every possible effort to ensure accuracy in its articles and apologizes for the mistake.

Due to a submission error, the article “Reduced Degree of Irritation During a Second Cycle of Ingenol Mebutate Gel 0.015% for the Treatment of Actinic Keratosis” (Cutis. 2015;95:47-51) contained the incorrect scale for local skin reactions (LSRs). The text in the Methods should have stated:

Using standardized photographic guides, 6 individual LSRs—erythema, flaking/scaling, crusting, 
swelling, vesiculation/pustulation, and erosion/ulceration—were assessed on a scale of 0 (none) to 
4 (severe), with higher numbers indicating more severe reactions.

The staff of Cutis^® makes every possible effort to ensure accuracy in its articles and apologizes for the mistake.

Due to a submission error, the article “Reduced Degree of Irritation During a Second Cycle of Ingenol Mebutate Gel 0.015% for the Treatment of Actinic Keratosis” (Cutis. 2015;95:47-51) contained the incorrect scale for local skin reactions (LSRs). The text in the Methods should have stated:

Using standardized photographic guides, 6 individual LSRs—erythema, flaking/scaling, crusting, 
swelling, vesiculation/pustulation, and erosion/ulceration—were assessed on a scale of 0 (none) to 
4 (severe), with higher numbers indicating more severe reactions.

The staff of Cutis^® makes every possible effort to ensure accuracy in its articles and apologizes for the mistake.

Due to a submission error, an acknowledgment was missing from the July 2014 article “The Great Mimickers of Rosacea” (Cutis. 2014;94:39-45).

Acknowledgements—The authors thank Jennifer Rullan, MD, San Diego, California, and Jose Gonzalez-Chavez, MD, San Juan, Puerto Rico, for their assistance.

Also, the order of the authors was incorrect in the July 2014 e-only article “Lepromatous Leprosy Associated With Erythema Nodosum Leprosum” (Cutis. 2014;94:E19-E20). The correct order is:

These articles have been corrected online.

Due to a submission error, an acknowledgment was missing from the July 2014 article “The Great Mimickers of Rosacea” (Cutis. 2014;94:39-45).

Acknowledgements—The authors thank Jennifer Rullan, MD, San Diego, California, and Jose Gonzalez-Chavez, MD, San Juan, Puerto Rico, for their assistance.

Also, the order of the authors was incorrect in the July 2014 e-only article “Lepromatous Leprosy Associated With Erythema Nodosum Leprosum” (Cutis. 2014;94:E19-E20). The correct order is:

These articles have been corrected online.

Due to a submission error, an acknowledgment was missing from the July 2014 article “The Great Mimickers of Rosacea” (Cutis. 2014;94:39-45).

Acknowledgements—The authors thank Jennifer Rullan, MD, San Diego, California, and Jose Gonzalez-Chavez, MD, San Juan, Puerto Rico, for their assistance.

Also, the order of the authors was incorrect in the July 2014 e-only article “Lepromatous Leprosy Associated With Erythema Nodosum Leprosum” (Cutis. 2014;94:E19-E20). The correct order is:

These articles have been corrected online.